The Additional Hetero Ring Is One Of The Cyclos In A Polycyclo Ring System Patents (Class 514/337)
-
Publication number: 20100204219Abstract: The invention relates to novel compounds of formula (I) wherein X, Y, Z represent independently from one another C or N, n stands for 1, 2, 3, m is 0 or 1, p stands for 0 or an integer from 1 to 6, R1, R2 represent independently from one another hydrogen, a halogen atom, a hydroxyl group, a C1-C3 alkyl group and a C1-C3 alkoxy group, R3 represents, independently from one another if p is not 0, hydrogen, halogen, a C1-C5 linear or branched alkyl, a carboxylyl, a carbomethoxyl, carboethoxyl, a benzyl, an acyl, a hydroxyl, a C1-C4 linear or branched alkoxyl, a trifluoromethyl, a cyano, a morpholino, a 1,3-dioxolyl, an N-acetylamidyl or an amidoyl group, a saturated 5-8 membered ring, a heterocyclic ring, optionally substituted by a C1-C3 alkyl, a hydroxyl or a benzyl group, a C1-C6 alkylsulfonyl, a mono or disubstituted C1-C5 alkyl group, a branched or a cyclic amine, R6 is H or part of a alicyclic, heteroalicyclic ring system, if m is 0 then C represents CF3 or a branched or unbranched C1-C4 alkyl group, if m=1Type: ApplicationFiled: December 11, 2007Publication date: August 12, 2010Inventors: Gabriel Garcia, Pierre Daram, Barbara Froesch, Guy Lemaillet, Leonardo Scapozza
-
Patent number: 7772256Abstract: The present invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.Type: GrantFiled: March 5, 2008Date of Patent: August 10, 2010Assignee: Astrazeneca ABInventors: Erwan Arzel, Britt-Marie Swahn, David Wensbo
-
Publication number: 20100190783Abstract: A Compound represented by the following general formula (1): wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.; and Z1 and Z2 each independently represent hydrogen or salts thereof or hydrates of the foregoing.Type: ApplicationFiled: March 29, 2010Publication date: July 29, 2010Inventors: Richard CLARK, Fumiyoshi MATSUURA, Kazunobu KIRA, Shinsuke HIROTA, Hiroshi AZUMA, Tadashi NAGAKURA, Tatsuo HORIZOE, Kimiyo TABATA, Kazutomi KUSANO, Takao OMAE, Atsushi INOUE
-
Publication number: 20100190823Abstract: Disclosed herein is a compound of the formula (I) therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: May 21, 2008Publication date: July 29, 2010Applicant: ALLEGERGAN INC.Inventors: Santosh C. Sinha, Todd M. Heidelbaugh, Ken Chow, Smita S. Bhat, Phong X. Nguyen, Michael E. Garst
-
Publication number: 20100184806Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of a peroxisome proliferator-activated receptor (PPAR) agent, optionally in combination with one or more neurogenic agents, to stimulate or increase a neurogenic response and/or to treat a nervous system disease or disorder.Type: ApplicationFiled: January 20, 2010Publication date: July 22, 2010Applicant: BrainCells, Inc.Inventors: Carrolee Barlow, Todd Carter, Andrew Morse, Kai Treuner, Kym Lorrain
-
Publication number: 20100179137Abstract: [Solving Means] The present inventors have conducted extensive studies on an EP4 receptor agonist, and as a result, found that a novel pyridone compound characterized in that the 1-position in the pyridone ring is substituted with a group having an acidic group such as a carboxyl group and the 6-position is bonded with an aromatic ring group via lower alkyl, lower alkylene, ether, or thioether, has an excellent EP4 receptor agonistic action, thereby completing the present invention. Since the compound of the present invention has an excellent EP4 receptor agonistic action and a blood flow increasing action in the hindlimb of a rat, it is useful as a pharmaceutical, in particular, an agent for treating peripheral arterial occlusive disease.Type: ApplicationFiled: June 6, 2008Publication date: July 15, 2010Inventors: Takashi Kamikubo, Fukushi Hirayama, Masanori Miura, Yuriko Komiya, Takao Okuda, Keisuke Maki
-
Patent number: 7754739Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.Type: GrantFiled: May 9, 2008Date of Patent: July 13, 2010Assignee: Vertex Pharmaceuticals IncorporatedInventors: Sara S. Hadida Ruah, Mark Miller, Brian Bear, Jinglan Zhou, Jason McCartney, Peter Grootenhuis
-
Publication number: 20100168121Abstract: Compositions and methods for treating disorders of the outer retina with compounds with 5-HT1A agonist activity are disclosed.Type: ApplicationFiled: March 8, 2010Publication date: July 1, 2010Applicant: ALCON, INC.Inventors: Robert J. Collier, JR., Michael A. Kapin, Mark R. Hellberg, Thomas R. Dean
-
Publication number: 20100168077Abstract: The present invention concerns 2-amino pyridine derivatives of formula 1 processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.Type: ApplicationFiled: March 31, 2008Publication date: July 1, 2010Applicant: UCB PHARMA, S.A.Inventor: Duncan Hannah
-
Patent number: 7745467Abstract: The invention concerns compounds of general formula (I), wherein n, X1, X2, X3, X4, Y and W are as defined herein. The invention also concerns a method for preparing said compounds and their therapeutic use.Type: GrantFiled: January 8, 2008Date of Patent: June 29, 2010Assignee: Sanofi-AventisInventors: Laurent Dubois, Yannick Evanno, Andre Malanda
-
Publication number: 20100151064Abstract: Described are compounds having a thiazolhydrazide scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said thiazolhydrazide compounds can be used for prophylaxis and/or treatment of neurodegenerative diseases and conditions.Type: ApplicationFiled: November 5, 2007Publication date: June 17, 2010Inventors: Eckhard Mandelkow, Eva-Maria Mandelkow, Markus Pickhardt, Jacek Biernat, David George Lloyd, Boris Schmidt, Gregor Larbig
-
Publication number: 20100137306Abstract: The invention relates to compounds of formulae I(a)-I(d): and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formulae I(a)-I(d) or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formulae I(a)-I(d) or a pharmaceutically acceptable derivative thereof.Type: ApplicationFiled: October 22, 2009Publication date: June 3, 2010Inventor: Laykea Tafesse
-
Publication number: 20100137371Abstract: The instant invention provides compounds of Formula (I) which are leukotriene biosynthesis inhibitors. Compounds of formula (I) are useful as anti-asthmatic, anti-allergic, anti-inflammatory, cytoprotective and anti-artherosclerotic agents.Type: ApplicationFiled: August 8, 2006Publication date: June 3, 2010Inventors: Carl Berthelette, Claude Dufresne, Lianhai Li, zhaoyin Wang
-
Publication number: 20100137322Abstract: The present invention relates to new compounds of formula (I) and to pharmaceutical composition containing said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof.Type: ApplicationFiled: April 22, 2008Publication date: June 3, 2010Applicant: ASTRAZENECA ABInventors: Yevgeni Besidski, Inger Kers, Martin Nylof, Lars Sandberg, Karin Skogholm
-
Publication number: 20100125073Abstract: The present invention relates to benzofuran and benzothiophene derivatives and compositions containing such compounds for the production of medicaments for the treatment of cancers of the central nervous system as monotherapy or combination with other agents.Type: ApplicationFiled: August 28, 2007Publication date: May 20, 2010Inventors: Olaf Weber, Verena Voehringer, Hans-Georg Lerchen, Frank-Thorsten Hafner, Joerg Keldenich, Karl-Heinz Schlemmer, Ursula Krenz, Bernd Riedl
-
Publication number: 20100119599Abstract: Provided are methods of treating or reducing the risk of developing beta-amyloid production, beta-amyloid deposition, beta-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer's amyloid by administering therapeutically effective amounts of polyhydroquinoline and dihydropyridine compounds which decrease Abeta production in cells. Further provided are methods for diagnosing diseases associated with cerebral accumulation of Alzheimer's amyloid in animals or humans by administering diagnostically effective amounts of polyhydroquinoline and dihydropyridine compounds which decrease Abeta production in cells.Type: ApplicationFiled: December 10, 2007Publication date: May 13, 2010Applicant: ARCHER PHARMACEUTICALS, INC.Inventors: Michael J. Mullan, Daniel Paris, Pancham Bakshi
-
Patent number: 7713999Abstract: Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt thereof, wherein: the dotted line represents an optional single bond; ?represents an optional double bond, n is 0-2; Q is cycloalkyl, optionally substituted by R13 and R14; R13 and R14 are independently selected from (C1-C6)alkyl, (C3-C8)cycloalkyl, —OH, (C1-C6)alkoxy, R27-aryl(C1-C6)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; or R13 and R14 together form a spirocyclic or a heterospirocyclic ring of 3-6 atoms, Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administerinType: GrantFiled: April 10, 2007Date of Patent: May 11, 2010Assignee: Schering CorporationInventors: Samuel Chackalamannil, Martin C. Clasby, William J. Greenlee, Yuguang Wang, Yan Xia, Enrico P. Veltri, Mariappan V. Chelliah
-
Patent number: 7709505Abstract: Compound of formula (I) wherein A is selected from pyridin-2-yl or thiazol-2-yl and R1, R2 and R3 are as described in the specification and their use in the treatment or prevention of a disease or medical conditions mediated through glucokinase.Type: GrantFiled: November 13, 2003Date of Patent: May 4, 2010Assignee: AstraZeneca ABInventors: Darren McKerrecher, John Wall Rayner
-
Patent number: 7700631Abstract: PDE4 inhibition is achieved by novel nitroxide compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formulas I-III: wherein A, B, D, R1, R2, R3, R7, R8, R9, R10 and R6 are as defined herein.Type: GrantFiled: March 20, 2006Date of Patent: April 20, 2010Assignee: Memory Pharmaceuticals CorporationInventors: Richard A. Schumacher, Elizabeth Doorly Graham, Allen T. Hopper, Ashok Tehim
-
Publication number: 20100093733Abstract: Compounds of formula (I): or pharmaceutically acceptable salts and esters thereof, are useful for the treatment of obesity, type II diabetes and the metabolic syndrome.Type: ApplicationFiled: February 15, 2008Publication date: April 15, 2010Applicant: PROSIDION LIMITEDInventors: Oscar Barba, Graham Dawson, William Gattrell, Martin James Procter, Chrystelle Marie Rasamison, Colin Peter Sambrook-Smith, Philippe Wong-Kai-In
-
Publication number: 20100093806Abstract: PDE4 inhibition is achieved by novel compounds, e.g., aminoindazole and aminobenzofuran analogs. The compounds of the present invention are of Formulas I and II: wherein R1, R2, R3, R4, R7 and R8 are as defined herein.Type: ApplicationFiled: December 17, 2009Publication date: April 15, 2010Inventors: Richard A. SCHUMACHER, Allen T. Hopper, Ashok Tehim
-
Publication number: 20100093694Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: ApplicationFiled: September 4, 2009Publication date: April 15, 2010Inventors: Kap-Sun Yeung, Kyle E. Parcella, John A. Bender, Brett R. Beno, Katharine A. Grant-Young, Ying Han, Piyasena Hewawasam, John F. Kadow, Andrew Nickel
-
Publication number: 20100056532Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.Type: ApplicationFiled: August 26, 2009Publication date: March 4, 2010Applicant: CalciMedica, Inc.Inventors: Gonul Velicelebi, Kenneth A. Stauderman, Jeffrey P. Whitten, Yazhong Pei, Jianguo Cao, Zhijun Wang, Evan Rogers, Brian Dyck, Jonathan Grey
-
Publication number: 20100048637Abstract: Compounds having the formula I, their methods of synthesis, and pharmaceutically acceptable salts of certain of them are provided in which the variables have the definitions described herein. Compositions including the compounds having the formula I-A in which the variables have the definitions described herein, and methods of using the compositions for the treatment of certain diseases mediated by the up-regulation of Smo are also disclosed.Type: ApplicationFiled: August 18, 2009Publication date: February 25, 2010Inventors: Shuo Lin, Zhen Yang
-
Publication number: 20100047357Abstract: The invention relates to a composition for topical application comprising as an active ingredient a peroxide and a retinoid wherein one of said peroxide and retinoid is in the form of first microparticles comprising a solid particulate matter of the active ingredient coated by a metal oxide layer and the other of said peroxide and retinoid is present in an uncoated free form or in a coated form of the active ingredient. The invention further relates to method for treating a surface condition in a subject using said composition, a method for preparing a composition exhibiting improved stability, and a kit comprising: (a) a first composition comprising a peroxide as a first active ingredient; and (b) a second composition comprising a retinoid as a second active ingredient; at least one of said first and said second active ingredient being coated by a metal oxide layer.Type: ApplicationFiled: February 3, 2008Publication date: February 25, 2010Applicant: SOL-GEL TECHNOLOGIES LTD.Inventors: Ofer Toledano, Hanan Sertchook, Natalia Loboda, Haim Bar-Simantov, Leora Shapiro, Raed Abu-Reziq
-
Publication number: 20100048513Abstract: The present invention is directed to a compound of formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof, and methods for treating inflammatory and serine protease mediated disorders.Type: ApplicationFiled: August 20, 2008Publication date: February 25, 2010Inventors: Michael J. Hawkins, Michael N. Greco, Eugene Powell, Lawrence de Garavilla, Bruce E. Maryanoff
-
Patent number: 7666863Abstract: The present invention relates to benzofuran derivatives and analogs, as well as compositions containing the same and to the use thereof for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the hepatitis C virus.Type: GrantFiled: May 24, 2007Date of Patent: February 23, 2010Assignees: ViroPharma Incorporated, WYETHInventors: Ashis K. Saha, Christopher J Burns, Alfred M. Del Vecchio, Thomas R. Bailey, Jason A. Reinhardt, Bheemashankar A. Kulkarni, Thomas H. Faitg, Hao Feng, Susan R. Rippin, Charles W. Blackledge, David J. Rys, Thomas A. Lessen, John Swestock, Yijun Deng, Theodore J. Nitz
-
Publication number: 20100022484Abstract: The present application relates to novel 4-chromenonyl-1,4-dihydropyridines, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.Type: ApplicationFiled: July 12, 2006Publication date: January 28, 2010Inventors: Alexander Kuhl, Peter Kolkhof, Heike Heckroth, Karl-Heinz Schlemmer, Ingo Flamme, Santiago Gigueroa Perez, Heike Gielen-Haertwig, Rolf Grosser, Jens-Kerim Ergüden, Dieter Lang
-
Patent number: 7652023Abstract: Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein.Type: GrantFiled: November 16, 2006Date of Patent: January 26, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Yufeng Wang, Wu Yang
-
Patent number: 7652125Abstract: A resin composition having high heat resistance and low dielectric constant after heat treatment, a varnish thereof and a semiconductor device using the same are provided by a resin composition including a compound having a structure represented by the general formula (1): wherein, “Ar” is an aromatic group; “a” is 0 or 1; R11 is an organic group having one or more carbon atoms and at least one is a group having an alicyclic structure; when “q” is an integer of 2 or more, R11s may be the same or different from each other; at least one of R1 to R5 and at least one of R6 to R10 on respective benzene rings are Ar-binding sites or R11-binding sites and the others of R1 to R5 and R6 to R10 are each hydrogen, a group having an alicyclic structure, an organic group having 1 to 10 carbon atoms, a hydroxyl group or a carboxyl group; when “a” is 0, at least one of R1 to R5 and R6 to R10 is a group having an alicyclic structure; “q” is an integer of 1 or more; and “X” is any of —O—, —NHCO—, —COHN—, —COO— and —OCO—.Type: GrantFiled: September 29, 2005Date of Patent: January 26, 2010Assignee: Sumitomo Bakelite Company, Ltd.Inventors: Takashi Enoki, Atsushi Izumi, Yumiko Yamamoto, Takahiro Harada
-
Publication number: 20100009973Abstract: The present invention provides a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. Compounds of formula (I) are also provided.Type: ApplicationFiled: April 30, 2007Publication date: January 14, 2010Applicant: AVEXA LIMITEDInventors: David Ian Rhodes, Katherine MacFarlane, Eric Dale Jones, William Issa, John Joseph Deadman, Neil Choi
-
Patent number: 7645777Abstract: A switching device is discloses that exhibits two stable resistance values to a voltage applied between electrodes. The switching device comprises thin films of a first electrode layer, an organic bistable material layer and a second electrode layer sequentially formed on a substrate, and the organic bistable material is a specified quinone compound.Type: GrantFiled: November 20, 2006Date of Patent: January 12, 2010Assignee: Fuji Electric Holdings Co., Ltd.Inventors: Nobuyuki Sekine, Haruo Kawakami, Hisato Kato, Keisuke Yamashiro, Kyoko Kato, Masami Kuroda
-
Publication number: 20100004208Abstract: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors.Type: ApplicationFiled: February 2, 2007Publication date: January 7, 2010Applicant: BIONOMICS LIMITEDInventors: Jason Hugh Chaplin, Gurmit Singh Gill, Damian Wojciech Grobelny, Bernard Luke Flynn, Gabriel Kremmidiotis
-
Publication number: 20090324570Abstract: The photostabilizing electronic excited state energy—particularly singlet state energy from retinoid compounds—has been found to be readily transferred to (accepted by) ?-cyanodiphenylacrylate compounds having an alkoxy radical in the four (para) position (hereinafter “alkoxycrylenes”) on one of the phenyl rings having the formula (I): wherein one of R1 and R2 is a straight or branched chain C1-C30 alkoxy radical, preferably C1-C8, more preferably methoxy, and the non-alkoxy radical R1 or R2 is hydrogen; and R3 is a straight or branched chain C1-C30 alkyl radical, preferably C2-C20. The alkoxycrylene compounds of formula (I) significantly increase the photostability of retinoid compounds in a composition by at least 3-fold and as much as 10-fold or greater. The ability of the alkoxycrylene compounds to stabilize the retinoid compound is concentration dependent, with the amount of retinoid photostabilization increasing with the concentration of the alkoxycrylene compound.Type: ApplicationFiled: July 31, 2009Publication date: December 31, 2009Applicant: HALLSTAR INNOVATIONS CORP.Inventors: Craig A. Bonda, Anna Pavlovic, Jean Zhang
-
Publication number: 20090318371Abstract: The present invention relates to a topical preparation for treating acne in the form of a gel and cream comprising Retinoid (Tazarotene or Adapalene) Antibiotic (Clindamycin Phosphate) and/or Keratolytic (Benzoyl Peroxide in microsponges) as active ingredients and a carrier formulated with all or some of the following components: Polyoxyl 35 castor oil Propylene glycol Glycerine, Carbomer, Triethanolamine, EDTA, Emulsifying nonionic wax (Polawax) Ethanol Antioxidants and Preservatives. The present invention advantages regarding state of the art compositions are based on the fact that the present antiacne composition contains a Retinoid, and Antibiotic and/or a Keratolytic agent which allow the control of every kind of acne from mild to vulgar offering less adverse effects.Type: ApplicationFiled: July 25, 2007Publication date: December 24, 2009Inventor: Fernando Ahumada Ayala
-
Patent number: 7632843Abstract: The present invention belongs to the field of pharmaceutical industry and relates to a new method for the treatment of psychostimulant addiction, in particular cocaine addiction, or pharmaceutically acceptable acid addition salts thereof, with a therapeutically effective amount of 9,10-didehydro-N-methyl-N-(2-propy-nyl)-6-methyl-8?-aminomethylergo-line in the form of free base or in the form of pharmaceutically acceptable addition salt, in particular the bimaleate salt, as well as pharmaceutical compositions containing said compound. In literature, the compound is also known under code LEK-8829. More particularly, present invention relates to a novel method of treatment for reduction of abstinence symptoms after cocaine withdrawal and for suppression the symptoms of craving for cocaine withdrawal and for suppression the symptoms of craving for cocaine reinforcement, and to the use of said active substance for the preparation of the pharmaceutical composition for the treatment of cocaine addiction.Type: GrantFiled: December 11, 2003Date of Patent: December 15, 2009Assignee: Lek Pharmaceuticals d.d.Inventors: Igor Krisch, Marko Zivin, Natasa Milivojevic, Rudolf Rucman, Breda Bole-Vunduk, Uros Urleb
-
Patent number: 7632820Abstract: Disclosed are compounds of the formulain which n is 0 or 1; X—Y is —CH?CH— or —CH2—CH2—; Z is —C(?O)—, —C(?S)— or —SO2—; R1 is C1-C12alkyl, C3-C8cycloalkyl or C2-C12alkenyl; and R2 is R3-Z-, R3—O-Z-, R4 or -Z-N(R6)(R7); Q is O or —N—R5; R3 and R4 are for example H, C1C12alkyl, C2-C12alkenyl, C2-C12alkynyl, C3-C12zcycloalkyl, C5-C12cycloalkenyl, aryl or heterocyclyl; R5 is for example H, C1-C8alkyl, hydroxy-C1-C8alkyl, C3-C8cycloalkyl, C2-C8alkenyl, C2-C8alkynyl, phenyl or benzyl; R6 and R7 are for example, H, unsubstituted or mono- to pentasubstituted C1-C12alkyl, unsubstituted or mono- to pentasubstituted C2-C12alkenyl or, if appropriate, an E/Z isomer, E/Z isomer mixture and/or tautomer thereof, in each case in free form or in salt form, are useful as pesticides.Type: GrantFiled: January 30, 2004Date of Patent: December 15, 2009Assignee: Merial LimitedInventors: Thomas Pitterna, Peter Maienfisch, Fiona Murphy Kessabi, Jerome Cassayre, Laura Quaranta, Pierre Jung
-
Publication number: 20090306055Abstract: The present invention is directed to compounds represented by the formula (1): B-D-Z (1), wherein B represent the following formula (B-1), A represents an optionally substituted imidazole or pyrazole group; E represents the following formula (1a): X represents an oxygen atom, the formula: SOu, or the formula: N—R9; Y represents a carbon atom or a nitrogen atom; D represents an oxygen atom, a sulfur atom or the formula (1a); Z represents (a chroman-2-yl group, a chroman-4-yl group, a 2,3-dihydrobenzofuran-2-yl group, a 2,3-dihydrobenzofuran-3-yl group, etc.) which is substituted with NHR10 or OR11)] or pharmaceutically acceptable salts thereof, and to antioxidants, therapeutic agents for kidney diseases or cerebrovascular disorder, and retinal oxidative damage inhibitors, which include the compounds as the active ingredient.Type: ApplicationFiled: May 15, 2009Publication date: December 10, 2009Applicant: NIPPON SODA CO., LTD.Inventors: Nobuhiro Umeda, Nobuo Mochizuki, Seiichi Uchida, Mitsumasa Takada, Seiichi Ikeyama, Shiro Tsubokura, Yasuyuki Shiinoki, Fumie Shirato, Hiroko Moroe
-
Publication number: 20090297476Abstract: The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.Type: ApplicationFiled: May 9, 2008Publication date: December 3, 2009Applicants: InterMune, Inc., Array Biopharma Inc.Inventors: SCOTT SEIWERT, STEVEN W. ANDREWS, LEONID BEIGELMAN, LAWRENCE M. BLATT, BRAD BUCKMAN, Kevin R. Condroski, Yutong Jiang, Robert J. Kaus, April L. Kennedy, Timonthy S. Kercher, Michael A. Lyon, Bin Wang
-
Publication number: 20090297576Abstract: Described herein are methods and medical devices used to deliver bioactive agents locally to patients in need of treatment and/or prevention of cardiovascular conditions Local delivery of protease-activated receptor 1 (PAR-1) antagonists are described herein from implantable medical devices including, but not limited to, stents.Type: ApplicationFiled: June 2, 2008Publication date: December 3, 2009Applicant: MEDTRONIC VASCULAR, INC.Inventors: Ayala Hezi-Yamit, Jennifer Wong
-
Patent number: 7618988Abstract: Compounds of formula I in which R has a meaning as indicated in claim 1, or one of their optical isomers or pharmaceutically acceptable salts, used for the treatment of extrapyramidal movement disorders and/or adverse effects in extrapyramidal movement disorders and/or for the treatment of extrapyramidal symptoms (EPS) induced by neuroleptics.Type: GrantFiled: August 12, 2002Date of Patent: November 17, 2009Assignee: Merck PatentgesellschaftInventors: Henning Böttcher, Ralf Devant, Maria Devant, legal representative, Gerd Bartoszyk, Hermann Russ, Frank Weber, Christoph Seyfried
-
Publication number: 20090281146Abstract: The present invention relates to a method of preparing N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide and pharmaceutically acceptable salts thereof, such as its sodium salt, and novel intermediate compounds useful in the synthesis of the aforementioned compound.Type: ApplicationFiled: July 17, 2009Publication date: November 12, 2009Applicant: Glenmark Pharmaceuticals, S.A.Inventors: Balasubramanian Gopalan, Laxmikant A. Gharat, Batchu Chandrasekhar, Bijukumar Gopinathan Pillai
-
Patent number: 7615570Abstract: Compounds having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein L, A, G, R1, R2 and R3 are as defined herein. These compounds are particularly useful in the treatment of pain, inflammatory hyperalgesia, and urinary dysfunctions, such as bladder overactivity and urinary incontinence.Type: GrantFiled: December 5, 2005Date of Patent: November 10, 2009Assignee: Abbott LaboratoriesInventors: Brian S. Brown, Tammie K. Jinkerson, Ryan G. Keddy, Chih-Hung Lee
-
Publication number: 20090275550Abstract: The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.Type: ApplicationFiled: April 11, 2007Publication date: November 5, 2009Inventors: James C. Barrow, Kelly-Ann S. Bieber, Rowena V. Cube, Mamio Christa Mattern, Thomas S. Reger, Youheng Shu, Zhi-Qiang Yang
-
Patent number: 7605158Abstract: The present invention provides a carbamoyl-type benzofuran derivative of the formula [1]: wherein Ring Z is a group of the formula: etc.; A is a single bond, and the like; Y is a cycloalkanediyl group, etc.; R4 and R5 are the same or different and each is an optionally substituted lower alkyl group, etc.; R1 is a halogen atom, etc.; Ring B of the formula: is an optionally substituted benzene ring; and R3 is a hydrogen atom. etc., or a pharmaceutically acceptable salt thereof, which is useful as an FXa inhibitor.Type: GrantFiled: September 24, 2004Date of Patent: October 20, 2009Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Takayuki Kawaguchi, Hidenori Akatsuka, Masamichi Morimoto, Tatsuya Watanabe, Toru Iijima, Jun Murakami
-
Publication number: 20090258906Abstract: The invention relates to compounds of the formula I in which R1, R2, A, B, X and Y have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.Type: ApplicationFiled: December 18, 2008Publication date: October 15, 2009Applicant: SANOFI-AVENTISInventors: Stephanie HACHTEL, Juergen DEDIO, Josef PERNERSTORFER, Stephen SHIMSHOCK, Carolina LANTER, Raymond KOSLEY
-
Publication number: 20090257953Abstract: The present invention is directed toward novel fluorine-18 labeled rhodamine dye derivatives and methods of making the same. The present invention is also directed toward methods of using novel fluorine-18 labeled rhodamine dye derivatives as positron emission tomography imaging agents and myocardial perfusion imaging agents.Type: ApplicationFiled: June 5, 2009Publication date: October 15, 2009Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Alan B. Packard, Tobias K. Heinrich, S. Ted Treves, Vijay Gottumukkala
-
Publication number: 20090253715Abstract: Compounds and methods useful for treating and prevention of cancer, particularly hormone-dependent breast cancer. Provided are compounds of formula I: wherein X is selected from O, N, S, SO, SO2, and S(CH2)n, wherein n=1-10; R1 and R2 may be the same or different and are selected from H, OH, OCH3, OCH2CH3, OCH2C6H5, NH2, NHCH3, N(CH3)2, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, C(CH3)3, NO2, F, Cl, Br, CF3, SH, SCH3, SCH2CH3, OCOCH3, OCOC(CH3)3, OCOCH2COOH, and CN; and R3 is a nitrogen-containing heterocyclic ring. Also provided are method for treating or preventing cancer in a subject by administering a therapeutically effective amount of a heteroaryl-containing isoflavone, or a pharmaceutically acceptable salt or prodrug thereof, to a subject in need of treatment.Type: ApplicationFiled: May 26, 2009Publication date: October 8, 2009Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Robert W. Brueggemeier, Young-Woo Kim, John C. Hackett
-
Patent number: 7589111Abstract: A taxane having a cyclopentyl ester substituent at C10, a keto substituent at C9, a hydroxy substituent at C2, a 2-thienyl substituent at C3? and an isopropoxycarbamate substituent at C3?.Type: GrantFiled: February 14, 2005Date of Patent: September 15, 2009Assignee: Florida State University Research Foundation, Inc.Inventors: Robert A. Holton, Phong Vu
-
Publication number: 20090221644Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.Type: ApplicationFiled: June 29, 2006Publication date: September 3, 2009Inventors: Stuart Edward Bradley, Matthew Colin Thor Fyfe, Lisa Sarah Bertram, William Gattrell, Martin James Procter, Chrystelle Marie Rasamison, Colin Peter Sambrook-Smith, Vilasben Kanji Shah, David French Stonehouse, Simon Andrew Swain, Gerard Hugh Thomas